Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 537

The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention

Open access
Sibbing, Dirk, Aradi, Daniel, Alexopoulos, Dimitrios, ten Berg, Jurrien, Bhatt, Deepak L., Bonello, Laurent, Collet, Jean-Philippe, Cuisset, Thomas, Franchi, Francesco, Gross, Lisa, Gurbel, Paul, Jeong, Young-Hoon, Mehran, Roxana, Moliterno, David J., Neumann, Franz-Josef, Pereira, Naveen L., Price, Matthew J., Sabatine, Marc S., So, Derek Y.F., Stone, Gregg W., Storey, Robert F., Tantry, Udaya, Trenk, Dietmar, Valgimigli, Marco, Waksman, Ron, Angiolillo, Dominick J.·2019·JACC: Cardiovascular Interventions

Abstract

Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary intervention. The availability of different P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) with varying levels of potency has enabled physicians to contemplate individualized treatment regimens, which may include escalation or deescalation of P2Y12-inhibiting therapy. Indeed, individualized and alternative DAPT strategies may be chosen according to the clinical setting (stable coronary artery disease vs. acute coronary syndrome), the stage of the disease (early vs. long-term treatment), and patient risk for ischemic and bleeding complications. A tailored DAPT approach may be potentially guided by platelet function testing (PFT) or genetic testing. Although the routine use of PFT or genetic testing in percutaneous coronary intervention-treated patients is not recommended, recent data have led to an update in guideline recommendations that allow considering selective use of PFT for DAPT deescalation. However, guidelines do not expand on when to implement the selective use of such assays into decision making for personalized treatment approaches. Therefore, an international expert consensus group of key leaders from North America, Asia, and Europe with expertise in the field of antiplatelet treatment was convened. This document updates 2 prior consensus papers on this topic and summarizes the contemporary updated expert consensus recommendations for the selective use of PFT or genotyping in patients undergoing percutaneous coronary intervention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jcin.2019.03.034

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 92 references

Cited by

See all 537

Metadata

Authors
Sibbing, D., Aradi, D., Alexopoulos, D., ten Berg, J., Bhatt, D. L., Bonello, L., Collet, J.-P., Cuisset, T., Franchi, F., Gross, L., Gurbel, P., Jeong, Y.-H., Mehran, R., Moliterno, D. J., Neumann, F.-J., Pereira, N. L., Price, M. J., Sabatine, M. S., So, D. Y. F., Stone, G. W., Storey, R. F., Tantry, U., Trenk, D., Valgimigli, M., Waksman, R., & Angiolillo, D. J.
Venue
JACC: Cardiovascular Interventions
Publisher
Elsevier BV
Published
2019-08
Volume
12
Issue
16
Pages
1521-1537
ISSN
  • 1876-7605 (ISSN-L)
  • 1936-8798
OpenAlex
W2951424940
Cited by
537
References
92
FWCI
49.56
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. https://app.cochat.ai/papers/10.1016/j.jcin.2019.03.034
The paper
Sibbing, D., Aradi, D., Alexopoulos, D., ten Berg, J., Bhatt, D. L., Bonello, L., Collet, J.-P., Cuisset, T., Franchi, F., Gross, L., Gurbel, P., Jeong, Y.-H., Mehran, R., Moliterno, D. J., Neumann, F.-J., Pereira, N. L., Price, M. J., Sabatine, M. S., So, D. Y. F., . . . Angiolillo, D. J. (2019). Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2019.03.034

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.